With a goal of providing multiple data sets demonstrating differentiated efficacy and safety in multiple ANCA-associated vasculitis (AAV) settings, InflaRx intends to begin two Phase 2 trials in 2027, with first data readout anticipated in 2028Phase 2 AAV izicopan program expected to include a placebo-controlled randomized study in patients with renal involvement with site initiation in early 2027, as well as an open-label “all-comers” study to demonstrate the ability to replace corticosteroidsI
Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar for November. Guggenheim Securities 3rd Annual Healthcare Innovation ConferenceNovember 9 – 11, 2026 in Boston, MAFireside chat on November 10 at 9:30 AM ESTInflaRx will also conduct one-on-one investor meetings on November 10th. A link to view the fireside chat live stream and i
Detailed price information for Achieve Life Sciences Inc (ACHV-Q) from The Globe and Mail including charting and trades.
Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development, effective October 1, 2026. Dr. Alperovich is a physician-scientist and nephrologist with more than two decades of experience in the global pharmaceutical industry, spanning senior leaders
Event to be hosted on November 3, 2026 at 8:00 AM ESTFeatured speakers will include Peter A. Merkel, MD, MPH and Prof. Dr. Jörg Köhl Jena, Germany, Sept. 21, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a virtual Capital Markets Event on November 3, 2026, from 8:00 AM EST / 2:00 PM CET to approximately 9:00 AM EST / 3:00 PM CET. The timing of the ev
InflaRx N.V (IFRX) has an average rating of buy and mean price target of $7.92, according to analyst
This is the newest page. Registered accounts read further back.